Shuttle Pharmaceuticals Dismisses Auditor Forvis Mazars With No Successor Named
SHPH sits 79% above its 52-week low of $2.576 on light trading volume (0.1× avg).
Summary
Shuttle Pharmaceuticals dismissed Forvis Mazars as its auditor effective after the Q3 2026 10-Q and has not yet engaged a replacement. The split is not dispute-driven, but it leaves an auditor gap at a company already dealing with a Nasdaq delisting notice and going-concern doubt.
Key Events · Corporate Governance and Compliance · SHPH
-
Auditor Dismissed, No Replacement Named
On October 16, 2026, the Audit Committee and full Board approved the dismissal of Forvis Mazars, LLP, effective following the Q3 2026 Form 10-Q. As of the filing, no successor independent registered public accounting firm has been engaged.
-
No Disagreements or Reportable Events
Forvis Mazars' reports for fiscal 2025 and 2024 were unqualified except for a going-concern explanatory paragraph, and the company reports no disagreements or reportable events other than the previously disclosed material weaknesses.
-
Material Weaknesses Carried Forward
The filing restates previously disclosed material weaknesses in accounting policies, segregation of duties, IT general controls, entity-level controls, and technical accounting expertise for complex transactions.
-
Compliance Gap Amid Listing Risk
The auditor departure follows the August 28, 2026 Nasdaq delisting notice for the late Q2 10-Q and the going-concern warning in that filing, leaving the company to engage a new firm before its next reporting cycle.
Analysis · SHPH · Life Sciences
Shuttle Pharmaceuticals is dropping its independent auditor effective after the Q3 10-Q, and it has not lined up a replacement. That leaves a gap in a core compliance function at a company already fighting a Nasdaq delisting notice from the late Q2 10-Q and carrying a going-concern warning. The dismissal itself is not a disagreement filing: Forvis Mazars' reports were clean apart from the going-concern paragraph, and the company reports no disagreements or reportable events beyond the previously disclosed material weaknesses. Still, an auditorless registrant must find a new firm and get it engaged before the next reporting cycle, and any delay compounds the listing risk.
How filings like this one have moved
In the 30 days to Oct 22, 2026, 36.9% of the 1013 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.77%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, SHPH was trading at $4.60 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $22M. The 52-week trading range was $2.58 to $44.40. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.